Give by midnight, Dec. 31, and your tax-deductible gift will be DOUBLED for kids!
Dr. Lin is double board certified in Pediatric Gastroenterology and Pediatric Transplant Hepatology at the Division of Gastroenterology, Hepatology and Nutrition, The Children's Hospital of Los Angeles. He participates in Multicenter Clinical Trial of the treatment of Erosive Esophagitis and Hepatitis C.
Pediatric Inflammatory Bowel Disease (IBD). Dr. Lin is the Principal Investigator (PI) for the treatment of Pediatric IBD with new biologics. Dr. Lin is also the PI for the management of Erosive Esophagitis (EE) with new PPI (Dexlansoprazole).
Dr. Lin also is specialized in the treatment of Hepatitis C. He is the PI for all oral medication (DAA) clinical trial for Hepatitis C, Genotype 1-6.
Dr. Lin is the member of Pediatric Liver Transplant Team at CHLA.
China Medical College, Taiwan
Mackay Memorial Hospital: Pediatrics
Mercy Hospital of BUffalo, Buffalo, New York
Children's Hospital of Buffalo, SUNY at Buffalo (Pediatric Gastroenterology)
Pediatrics and Pediatric Gastroenterology: American Board of Pediatrics
North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN); American Gastroenterological Association (AGA); American Academy of Pediatrics (AAP); Society of Pediatric Research (SPR), American Association of Study of Liver Diseases (AASLD).
Books and Chapters
Peered Review Articles
· Lin CH, Vijesurier R, Ho YS, Schipper R, Tolia V, Moshier J, Majumdar A: Expression of intestinal ornithine decarboxylase during postnatal development in neonatal rats. Biochim Biophys Acta, 1589:298-304, 2002. PMID: 12031796
· El-Baba M, Padilla M, Houston C, Madani S, Lin CH, Thomas R, Tolia V: A prospective study comparing oral sodium phosphate solution to a bowel cleansing preparation with nutrition food package in children. J Pediatr Gastroenterol Nutr, 42:174-177, 2006. PMID: 16456411
Abstract and Presentations
Current research in 1) Pediatric IBD (PI for Multicenter Trials of new Biologics for treatment of Pediatric IBD, 2) Pediatric Erosive Esophagitis (EE) (PI for Multicenter Trials for treatment of Pediatric EE with new PPI (Dexlansoprazole), 3) Hepatitis C in Pediatrics (PI for Multicenter Trial of all oral DAA for the treatment of Hepatitis C in Pediatrics, 4) Depressed regulatory T lymphocytes as the possible pathogenesis of IBD (Collaboration with Adult GI program at USC).